New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

ASPIRE establishes a new way of operating, changing the practice of how stakeholders come together to drive innovation and accelerate progress. ASPIREestablishes a new way of operating, changing the practice of how stakeholders come together to drive innovation and accelerate progress. "Patients with amyloidosis often experience various challenges to arrive at a proper diagnosis, and expediting the diagnostic journey is critical to the overall care and management of these patients," said...

BOSTON, Mass., 04/10/2022 (informazione.news - comunicati stampa - scienza e tecnologia)

establishes a new way of operating, changing the practice of how stakeholders come together to drive innovation and accelerate progress.

"Patients with amyloidosis often experience various challenges to arrive at a proper diagnosis, and expediting the diagnostic journey is critical to the overall care and management of these patients," said Sonal Bhatia , MD, Chief Medical Officer, Rare Disease, Pfizer. "Pfizer is proud to join ARC's initiative as a Co-Chair of the Executive Steering Committee. We look forward to collaborating on the development of innovative solutions that aim to accelerate appropriate diagnosis and improve care and health outcomes for patients with amyloidosis." 

At launch, member companies include:

Working synergistically within and across shared interests, with combined resources, and within a framework that supports reciprocal learning and partnership, is positioned to demonstrate what can be done when leaders work together to elevate community-led solutions on behalf of rare disease patients. "The level of commitment from the member companies in is remarkable and speaks to ARC's strong leadership and track record of mobilizing stakeholders to collectively face challenges head-on," Kristina Bowyer , Vice President of Patient Centric Drug Development at Ionis Pharmaceuticals and Co-Chair of 's Executive Steering Committee said. "Working together as a Collaborative, we are well-poised to break down drivers of health disparities and take steps to meaningfully close the gaps in unmet need within the amyloidosis community."

To learn more about and our current initiatives please visit www.arci.org/aspire/ or contact ARC's Executive Director of Strategic Partnerships, Vanessa Boulanger , vboulanger@arci.org. 

The Amyloidosis Research Consortium (ARC), founded in 2015, is a nonprofit organization dedicated to driving advances in the awareness, science, and treatment of amyloid diseases. ARC's mission is to harness the power of collaboration and innovation to advance science, and both improve and extend the lives of those with amyloidosis. ARC operates by building strategic collaborations that bring the ecosystem of stakeholders together to deliver value while partnering on programs that have the greatest impact for patients in both the near and long-term. Working with partners in industry, government, and academia, ARC seeks to spark innovation and to bring promising treatments from labs to clinics, supporting and empowering patients, families, caregivers, physicians, and researchers.

 

Logo - https://mma.prnewswire.com/media/1911346/Amyloidosis_Research_Consortium_Logo.jpg
Photo - https://mma.prnewswire.com/media/1911347/ASPIRE_Social_Media_Graphic.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/new-initiative-brings-leading-life-sciences-companies-together-to-drive-collective-impact-in-awareness-diagnosis-care-and-health-equity-for-patients-with-amyloidosis-301638301.html